Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03100474 · ClinicalTrials.gov registry record

Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:

A clinical trial of Parkinson's Disease and Essential Tremor, sponsored by InSightec.

Active
Registry status
500
Enrollment target
9
Study locations

NCT03100474 is a study of Parkinson's Disease and Essential Tremor that is active but no longer recruiting, run by InSightec. The registered enrollment target is 500 participants, below the 639-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (22% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03100474, a study of Parkinson's Disease and Essential Tremor, is active but no longer recruiting, sponsored by InSightec.

ACTIVE NOT RECRUITING
Registry status
500 participants
Enrollment target
9
Study locations

Study Summary

A global post approval study to collect safety and effectiveness data related to ExAblate Neuro for the treatment of certain disorders such as Essential Tremor, Parkinson's Movement Disorders, or Neuropathic Pain within the thalamus and/or pallidum.

Study Locations (9)

Other

  • Rambam Healthcare Campus - Haifa
  • Sheba Medical Center - Ramat Gan
  • Chang Bing Show Chwan Memorial Hospital - Chang-hua

California

  • Stanford University - Stanford

Maryland

  • University of Maryland - Baltimore

Pennsylvania

  • University of Pennsylvania - Philadelphia

Virginia

  • University of Virginia - Charlottesville

Washington

  • Swedish Neuroscience Institute - Seattle

Ontario

  • Sunnybrook - Toronto

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2016-12
Est. Completion 2026-06

Sponsor

InSightec

38 total trials

What the Registry Record Tells You About NCT03100474

The ClinicalTrials.gov registry entry for NCT03100474 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 639-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (22% lower). The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 0 interventions.

NCT03100474 reports 9 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT03100474 about?

NCT03100474 is a clinical study titled "Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:". A global post approval study to collect safety and effectiveness data related to ExAblate Neuro for the treatment of certain disorders such as Essential Tremor, Parkinson's Movement Disorders, or Neuropathic Pain within the thalamus and/or pallidum.

What is the current status of trial NCT03100474?

This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2016-12. Estimated completion is 2026-06.

What conditions does trial NCT03100474 study?

This clinical trial studies the following conditions: Parkinson's Disease, Essential Tremor, Neuropathic Pain, Movement Disorders.

Who is sponsoring clinical trial NCT03100474?

This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03100474 being conducted?

This trial has 9 study locations across California, Maryland, Pennsylvania, Virginia, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Parkinson's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.